Alisol B, a triterpene from Alismatis rhizoma (dried rhizome of Alisma orientale), inhibits melanin production in murine B16 melanoma cells by Yoshida, Ichiro et al.
1 
Alisol B, a triterpene from Alismatis rhizoma (dried rhizome of Alisma 1 
orientale), inhibits melanin production in murine B16 melanoma cells 2 
3 
Ichiro Yoshida1, Chihiro Ito2, Shinya Matsuda2, Akihiko Tsuji2, 3, Noriyuki Yanaka4, and Keizo Yuasa2, 3, * 4 
5 
1 Laboratory of Nutritional Science, Department of Food Science and Nutrition, Shikoku Junior College, 6 
Ohjin, Tokushima 771-1192, Japan 7 
2 Department of Biological Science and Technology, Tokushima University Graduate School, 8 
Minamijosanjima, Tokushima 770-8506, Japan 9 
3 Department of Bioscience and Bioindustry, Tokushima University Graduate School, Minamijosanjima, 10 
Tokushima 770-8513, Japan 11 
4 Department of Molecular and Applied Bioscience, Graduate School of Biosphere Science, Hiroshima 12 
University, Higashi-Hiroshima, 739-8528, Japan 13 
14 
* Corresponding author at: Department of Bioscience and Bioindustry, Tokushima University Graduate15 
School, Minamijosanjima, Tokushima 770-8513, Japan. Fax: +81-88-655-3161. 16 
E-mail address: kyuasa@tokushima-u.ac.jp.17 
18 
19 
This is an electronic version of an article published in Bioscience, Biotechnology, and Biochemistry 81, 3, 534-540, 2017. 
Bioscience, Biotechnology, and Biochemistry is available online at: www.tandfonline.com/10.1080/09168451.2016.1268042.
2 
 
Abstract  1 
To develop new whitening agents from natural products, we screened 80 compounds derived from 2 
crude drugs in Kampo medicine in a melanin synthesis inhibition assay using murine B16 melanoma cells. 3 
The screen revealed that treatment with alisol B, a triterpene from Alismatis rhizoma, significantly 4 
decreased both melanin content and cellular tyrosinase activity in B16 cells. However, alisol B did not 5 
directly inhibit mushroom tyrosinase activity in vitro. Therefore, we investigated the mechanism 6 
underlying the inhibitory effect of alisol B on melanogenesis. Alisol B suppressed mRNA induction of 7 
tyrosinase and its transcription factor, microphthalmia-associated transcription factor (MITF). 8 
Furthermore, alisol B reduced the phosphorylation of CREB and maintained the activation of ERK1/2. 9 
These results suggest that the reduction in melanin production by alisol B is due to the downregulation of 10 
MITF through the suppression of CREB and activation of ERK, and that alisol B may be useful as a new 11 
whitening agent. 12 
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Introduction 1 
Melanin is synthesized in the melanosomes of melanocytes, and plays a crucial role in protecting the 2 
skin from the harmful effects of ultraviolet radiation.1) Melanin synthesis or melanogenesis is mainly 3 
regulated by 3 melanogenic enzymes: tyrosinase (polyphenol oxidase; EC 1.14.18.10), tyrosinase-related 4 
protein-1 (TRP-1), and tyrosinase-related protein-2 (TRP-2). Tyrosinase is the rate-limiting enzyme in the 5 
melanogenic process, which catalyzes 2 different reactions: the hydroxylation of tyrosine to 6 
3,4-dihydroxyphenylalanine (DOPA) and oxidation of DOPA to dopaquinone.2) In the absence of thiol 7 
substances, dopaquinone is first converted to dopachrome and then to 5,6-dihydoxyindole or 8 
indol-5,6-quinone 2-carboxylic acid (DHICA). TRP-2 catalyzes the conversion of dopachrome to DHICA, 9 
and TRP-1 catalyzes the oxidation of DHICA.3) These melanogenic enzymes contain the consensus 10 
binding site for microphthalmia-associated transcription factor (MITF), a member of the basic 11 
helix-loop-helix-leucine zipper family of transcription factors, in their promoters, and are transcriptionally 12 
induced by MITF.4)  13 
α-Melanocyte-stimulating hormone (α-MSH), which is a tridecapeptide from the precursor 14 
proopiomelanocortin and belongs to the melanocortin family, binds and activates the G-protein-coupled 15 
melanocortin 1 receptor in melanocytes and in turn stimulates melanogenesis via the elevation of 16 
intracellular cAMP levels. cAMP-elevating agents such as forskolin (an adenylate cyclase activator) and 17 
3-isobutyl-1-methylxanthine (IBMX) (a phosphodiesterase inhibitor) also stimulate melanin synthesis. An 18 
increase in intracellular cAMP levels leads to protein kinase A (PKA) activation, which subsequently 19 
phosphorylates the transcription factor cAMP-responsive element-binding protein (CREB) at Ser133. The 20 
phosphorylated active form of CREB binds to the CRE motif of the MITF promoter and activates MITF 21 
transcription.5) Thus, the cAMP/PKA/CREB pathway induces the expression of tyrosinase and its related 22 
proteins via MITF activation, thereby leading to the stimulation of melanogenesis.6) On the other hand, 23 
the extracellular signal-regulated kinase (ERK) pathway is also involved in the regulation of melanin 24 
production.7) Previous reports showed that the inhibition of ERK induced B16 melanoma cell 25 
differentiation and increased tyrosinase activity, and that the inhibition of mitogen-activated protein 26 
kinase kinase (MEK) activity by anthrax lethal toxin induced melanin production in human melanoma 27 
cells.7, 8) In addition, it has been suggested that ERK activation leads to the phosphorylation and 28 
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degradation of MITF, resulting in a reduced tyrosinase level and decreased melanogenesis.9)  1 
Because excessive production of melanin and its accumulation in the epidermis cause abnormal 2 
hyperpigmentation of the skin, such as melisma, freckles, and senile lentigines, the development of 3 
melanogenesis inhibitors has been focused. Kojic acid and arbutin have been often used as cosmetic 4 
agents for skin whitening; however, they are associated with some problems. For example, kojic acid 5 
causes allergic reactions such as contact dermatitis and sensitization if used for long stretches of time.10, 11) 6 
Therefore, the discovery of safer and more effective whitening agents is required, and some potent 7 
tyrosinase inhibitors, including luteolin, oxyresveratrol, and quercetine, have been identified from natural 8 
plants.12-14) Glabridin, an isoflavane isolated from the roots of licorice (Glycyrrhiza glabra), also inhibits 9 
tyrosinase activation, and is currently used as a skin-whitening ingredient. Licorice is one of the most 10 
frequently-used crude drugs in Kampo medicines (traditional Japanese herbal medicines). Although many 11 
crude drug components have been identified, it is not yet fully understood whether any of these 12 
components can inhibit melanin biosynthesis. Therefore, we investigated the potential anti-melanogenic 13 
effects of 80 compounds derived from crude drugs in Kampo medicines. We identified alisol B, a 14 
triterpene extracted from Alismatis rhizoma, as a novel melanogenesis inhibitor in murine B16 melanoma 15 
cells.  16 
 17 
Materials and methods 18 
Cell culture. Murine B16 melanoma cells were cultured in DMEM supplemented with 10% fetal 19 
bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin at 37°C in 5% CO2. 20 
 21 
Cell viability assay. B16 cells were seeded at a density of 5 x 103 cells per well in 96-well culture 22 
plates. After 24 hours, the cells were treated with 10 μM natural products or dimethyl sulfoxide (DMSO) 23 
in the presence of 20 μM forskolin and 100 μM IBMX for 72 hours. All natural products were dissolved 24 
in 100% DMSO at a concentration of 10 mM, and the final concentration of DMSO in the culture 25 
medium was 0.1%. The relative viable cell number was determined by the 3-(4, 5-dimethylthiazol-2yl)-2, 26 
5-diphenyltetrazolium bromide (MTT) assay. After a 2-hour incubation with MTT, the resulting formazan 27 
crystals were dissolved in DMSO. The absorbance at 570 nm was determined using the Infinite M200 28 
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plate reader (TECAN Japan).  1 
 2 
Measurement of melanin contents. B16 cells were seeded at a density of 2 x 104 cells into 24-well 3 
culture plates. After 24 hours, cells were pretreated with 10 μM natural products or DMSO for 30 min 4 
and stimulated with 20 μM forskolin and 100 μM IBMX. After 72 hours, cells were washed with ice-cold 5 
PBS and lysed with 1 N NaOH at 100 °C for 1 hour. After centrifugation at 16,000 x g for 20 min, the 6 
absorbance of the supernatant was measured at 405 nm. 7 
 8 
Assay of cellular and in vitro tyrosinase. Tyrosinase activity was assessed by determining the catalysis 9 
of L-DOPA to dopachrome. To measure cellular tyrosinase activity, B16 cells were seeded at a density of 10 
2 x 104 cells in 24-well culture plates. After 24 hours, cells were pretreated with 1 μM alisol B (Wako 11 
Pure Chemical Industries, Japan) or DMSO for 30 min, followed by stimulation with 20 μM 12 
forskolin/100 μM IBMX or 0.1 μM α-MSH (GenScript, purity > 95%) for 72 hours. The cells were lysed 13 
with 100 mM sodium phosphate buffer (pH 6.8) containing 1% Triton X-100, 10 μg/ml aprotinin, and 10 14 
μg/ml leupeptin. After centrifugation at 10,000 x g for 10 min, aliquot (100 μl) of the supernatant was 15 
mixed with 100 μl of a substrate solution containing100 mM sodium phosphate buffer (pH 6.8) and 0.5 16 
mM L-DOPA, and incubated for 30 min at 37 °C. To monitor the production of dopachrome, the 17 
absorbance at 475 nm was measured using the microplate reader. 18 
 19 
Reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) and immunoblotting. 20 
For RT-qPCR analysis, total RNA extracted from B16 cells was reverse transcribed using ReverTra Ace 21 
qPCR RT Master Mix with gDNA Remover (TOYOBO, Japan). Quantitative real-time PCR was 22 
conducted using ABI Prism 7000 Sequence Detection System (Applied Biosystems) with Power SYBR 23 
Green PCR Master Mix (Applied Biosystems) as previously described.15) The following specific primers 24 
were used: tyrosinase, forward 5’-GTCGTCACCCTGAAAATCCTAACT-3’ and reverse 25 
5’-CATCGCATAAAACCTGATGGC-3’; MITF, forward 5’-GTATGAACACGCACTCTCGA-3’ and 26 
reverse 5’-GTAACGTATTTGCCATTTGC-3’; and glyceraldehyde-3-phosphate dehydrogenase 27 
(GAPDH), forward 5’- GTGTCCGTCGTGGATCTGA -3’ and reverse 5’- 28 
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CCTGCTTCACCACCTTCTTG -3’. GAPDH was used as an internal control. 1 
For immunoblotting, cells were lysed with lysis buffer [20 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1 2 
mM EDTA, 1% Nonidet P-40, 10 μg/ml aprotinin, and 10 μg/ml leupeptin]. After centrifugation at 3 
10,000 × g for 10 min, the supernatants were performed for immunoblotting with antibodies against 4 
CREB, phospho-CREB, ERK1/2, phospho-ERK1/2, MEK1/2, phospho-MEK1/2 (Cell Signaling 5 
Technology), MITF, or β-actin (SantaCruz Biotechnology). 6 
 7 
Statistical analysis. All experiments were performed multiple times to confirm their reproducibility. 8 
One representative set of data was shown in the figures. Immunoblot band intensities were quantified 9 
using Image J software (NIH). Data were expressed as the mean ± standard error, and statistical analysis 10 
was performed by Student's t-test or one-way analysis of variance (ANOVA) with Tukey’s multiple 11 
comparison test using GraphPad Prism (GraphPad Software). 12 
 13 
Results 14 
Identification of melanogenesis inhibitors from a compound library derived from crude drugs in Kampo 15 
medicine 16 
We first screened 80 chemically defined natural products in traditional Japanese herbal medicines 17 
(Kampo medicines) for their ability to inhibit melanin pigmentation in murine B16 melanoma cells. To 18 
induce melanin pigmentation, B16 cells were stimulated with a combination of 20 μM forskolin and 100 19 
μM IBMX for 72 hours, resulting in a significant increase (> 2-fold) in melanin production (Fig. 1A). 20 
After pretreatment with the compounds at a concentration of 10 μM, cellular melanin contents in 21 
forskolin/IBMX-stimulated cells were examined. Among the 80 compounds that we tested, 8 compounds 22 
(alisol B, berberine chloride, bergenin, coptisine chloride, corydaline, glabridin, loganin, and nodakenin) 23 
apparently decreased melanin pigmentation stimulated with forskolin/IBMX (data not shown). Therefore, 24 
we measured melanin contents in B16 cells treated with forskolin/IBMX in the presence and absence of 25 
these 8 compounds. As shown in Fig. 1A, treatment with alisol B, berberine chloride, coptisine chloride, 26 
corydaline, or glabridin at 10 μM significantly inhibited the increase in melanin production stimulated 27 
with forskolin/IBMX. Next, we examined the cytotoxicity of these compounds in B16 cells by the MTT 28 
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assay. B16 cells were treated with each compound at 10 μM in the presence of forskolin/IBMX for 72 1 
hours. As shown in Fig. 1B, berberine chloride, coptisine chloride, and nodakenin had cytotoxic effects 2 
on cells, but alisol B and glabridin did not affect cell viability. Because glabridin, a major active 3 
flavonoid in G. glabra, has been reported to possess anti-melanogenic activity via the inhibition of 4 
tyrosinase,16) alisol B was chosen as a candidate anti-melanogenic agent (Fig. 1C). The percent inhibition 5 
of melanin production by alisol B at 0.1 μM, 1 μM, and 10 μM was 15%, 69%, and 94%, respectively, 6 
and its 50% inhibitory concentration (IC50) was 440 nM (data not shown). This result indicates that alisol 7 
B clearly exhibits enough inhibitory activity to reduce melanin production in B16 cells at a concentration 8 
of 1 μM. Therefore, for further experiments, alisol B was used at a concentration of 1 μM. 9 
 10 
Effect of alisol B on melanin production and tyrosinase activity in B16 cells 11 
Alisol B is one of the major triterpene constituents and is known a bioactive component of A. rhizoma 12 
(dried rhizome of Alisma orientale).17) Although A. rhizoma is well-known in Chinese traditional 13 
medicine and has been used to treat diuresis and hyperlipidemia,18) no previous study has examined its 14 
anti-melanogenic activity. Therefore, we examined whether A. rhizoma reduces melanin synthesis 15 
stimulated with forskolin/IBMX. In addition, we tested the effect of A. rhizoma and alisol B on 16 
α-MSH-induced melanin pigmentation. B16 cells pretreated with alisol B or A. rhizoma were stimulated 17 
with forskolin/IBMX or α-MSH for 72 hours, following which their melanin content was measured. As 18 
shown in Fig. 2A and B, stimulation with forskolin/IBMX and α-MSH resulted in an approximately 19 
2-fold increase in melanin content compared with the control. Alisol B efficiently decreased melanin 20 
production induced by both forskolin/IBMX and α-MSH compared with glabridin, a potent tyrosinase 21 
inhibitor. On the other hand, A. rhizoma had no or little influence on the production of melanin in any 22 
stimulated cells, suggesting the existence of components that counteract the effect of alisol B.  23 
Because tyrosinase is the rate-limiting enzyme for melanin synthesis, we next examined the inhibitory 24 
effect of alisol B on cellular tyrosinase activity in forskolin/IBMX- or α-MSH-stimulated B16 cells. As 25 
shown in Fig. 2C and D, B16 cells showed increased tyrosinase activity upon exposure to 26 
forskolin/IBMX and α-MSH. Alisol B significantly suppressed both forskolin/IBMX- and 27 
α-MSH-induced cellular tyrosinase activity. Furthermore, we measured the inhibitory effect of alisol B on 28 
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in vitro mushroom tyrosinase inhibition assay using L-DOPA as a substrate. Alisol B (final concentration 1 
at 1 μM and 10 μM) had no inhibitory effect on mushroom tyrosinase activity, although reduced 2 
glutathione, a compound that inhibits tyrosinase activity, significantly inhibited (data not shown). These 3 
results suggest that the inhibition of melanin synthesis by alisol B is accompanied by a parallel decrease 4 
in tyrosinase activity, perhaps by the suppression of tyrosinase expression. 5 
 6 
Effect of alisol B on expression of tyrosinase and MITF 7 
We elucidated whether alisol B influences the mRNA expression of tyrosinase. Real-time quantitative 8 
PCR analysis revealed that forskolin/IBMX treatment dramatically increased the mRNA level of 9 
tyrosinase, and that its induction was significantly inhibited by alisol B (Fig. 3A). Furthermore, the 10 
mRNA expression of MITF, a key transcription factor that regulates the expression of the tyrosinase gene, 11 
was also measured. As shown in Fig. 3B, alisol B slightly but significantly reduced the induction of MITF 12 
mRNA by forskolin/IBMX. In addition, B16 cells pretreated with alisol B were stimulated with 13 
forskolin/IBMX for 30 min or 60 min, and the level of MITF protein in these cells was determined by 14 
immunoblot analysis. Fig. 3C shows that MITF protein level was decreased by pretreatment with alisol B. 15 
These results indicate that alisol B represses tyrosinase expression partially via the reduction of MITF 16 
mRNA and protein levels, leading to the down-regulation of melanin synthesis. 17 
 18 
Effects of alisol B on the signaling pathway involved in melanogenesis 19 
MITF expression is induced by CREB activated through phosphorylation at Ser133.19) Thus, we 20 
performed immunoblot analysis to determine whether alisol B affects CREB phosphorylation. As shown 21 
in Fig. 4A, the phosphorylation of CREB at Ser133 was hardly detectable in unstimulated B16 cells, but 22 
was increased at 30 min and further increased at 60 min after stimulation with forskolin/IBMX. 23 
Compared with untreated cells, alisol B remarkably decreased CREB phosphorylation by 61% after 24 
stimulation for 60 min, although it had no effect on CREB phosphorylation after 30 min. This indicates 25 
that alisol B downregulates MITF expression partially through the inhibition of CREB phosphorylation.  26 
In addition to the cAMP/PKA/CREB pathway, the mitogen-activated protein kinase (MAPK) signaling 27 
pathway is also involved in melanogenesis.7, 8, 20) The activation of ERK MAPK leads to MITF 28 
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ubiquitination and degradation, and thus inhibits melanin synthesis.9, 21) Therefore, we investigated 1 
whether alisol B influences ERK activation. After forskolin/IBMX stimulation, ERK1/2 was transiently 2 
phosphorylated with a peak at 30 min, and then diminished (Fig. 4B). Pretreatment with alisol B induced 3 
prolonged phosphorylation of ERK1/2, which remained strongly phosphorylated after 60 min. Similarly, 4 
the phosphorylation of MEK1/2, an upstream kinase of ERK, was also sustained by alisol B treatment 5 
(Fig. 4C). Finally, we examined whether the inhibition of the MEK/ERK pathway affects MITF reduction 6 
by Alisol B. B16 cells were treated with Alisol B in the presence or absence of a MEK-specific inhibitor 7 
U0126, followed by stimulation with forskolin/IBMX for 30 min. As shown in Fig. 4D, MITF protein 8 
level was significantly reduced by alisol B and the reduction was slightly recovered by U0126. These 9 
results indicate that alisol B plays a dual role, namely the inhibition of the cAMP/PKA/CREB pathway 10 
and activation of the MEK/ERK pathway, thereby inducing the downregulation of MITF.  11 
 12 
Discussion 13 
The development of natural products from various plant sources that inhibit melanin formation and 14 
tyrosinase activity has been actively pursued, because the existing skin-whitening products have been 15 
reported to exhibit some side effects. To develop safer and more efficient pharmaceutical and cosmetic 16 
products, we focused on chemically defined natural products in Kampo medicines, which are traditional 17 
Japanese herbal medicines. In the present study, we identified alisol B 18 
[(23S,24R)-24,25-epoxy-11b,23-dihydroxy-8a,9b,14b-dammar-13(17)-en-3-one] as an anti-melanogenic 19 
compound, whose activity is higher than that of a known tyrosinase inhibitor, glabridin. Alisol B is one of 20 
the major active constituents of A. rhizoma, which also contains alisol A, C, and their related compounds 21 
as active triterpenoids.17) Although A. rhizoma has been used because of its diuretic, hypolipidemic, and 22 
anti-inflammatory properties,18) its anti-melanogenic activity has not been studied. We found that A. 23 
rhizoma has little anti-melanogenic activity. Furthermore, alisol A 24 
[(23S,24R)-11b,23,24,25-tetrahydroxydammar-13(17)-en-3-one], which was also tested in this study, had 25 
a much lower inhibitory effect than alisol B (27%-55% alisol A vs. 64%-75% alisol B inhibitory activity 26 
at 10 μM) (data not shown). A previous study revealed that alisol B induces autophagy via the inhibition 27 
of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase pump, whereas alisol A exhibits a much lower 28 
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inhibitory effect.22) These results suggest that a slight structural difference between alisol A and B may 1 
exert a distinct influence on the physiological function. 2 
Although alisol B significantly inhibited cellular tyrosinase activity stimulated with forskolin/IBMX 3 
and α-MSH, it (even at 10 μM) did not affect tyrosinase activity in an in vitro system using mushroom 4 
tyrosinase. Because tyrosinase is the rate-limiting enzyme in the melanogenic process, most of the 5 
strategies for the development of skin-whitening agents are based on the inhibition of tyrosinase activity. 6 
In fact, tyrosinase inhibitors, such as kojic acid and arbutin, are used in cosmetic products and as 7 
depigmenting agents for hyperpigmentation. On the other hand, the suppression of tyrosinase gene 8 
expression is also a target for the development of skin-whitening products. A recent report has 9 
demonstrated that hispolon, a compound of Phellinus linteus, inhibits melanogenesis through the 10 
down-regulation of tyrosinase and MITF expression.23) The inhibitory effect of alisol B on melanogenesis 11 
also seems to be attributed to the suppression of tyrosinase gene expression rather than to the direct 12 
inhibition of tyrosinase activity. 13 
The promoters of tyrosinase, TRP-1, and TRP-2 possess the consensus binding site for MITF, which is 14 
a master regulator of melanocyte development, and their expression is activated by MITF. Although alisol 15 
B significantly reduced the induction of tyrosinase and MITF mRNA by forskolin/IBMX, it did not affect 16 
the expression of TRP-1 and TRP-2 mRNA (data not shown). Chloroform extracts of fermented Viola 17 
mandshurica inhibited the mRNA expression of tyrosinase and MITF, but not of TRP-1 and TRP-2, in 18 
B16 cells.24) On the other hand, acetoside, a phenylpropanoid glycoside isolated from the leaves of 19 
Rehmannia glutinosa, downregulated the expression of tyrosinase and TRP-1, but not of TRP-2.25) This 20 
suggests that molecules other than MITF, for example, other transcription factors including repressors, 21 
may be also involved in the expression of tyrosinase and tyrosinase-related proteins, and that their 22 
enzymes may exhibit different expression patterns depending on the compounds. 23 
MITF protein levels are regulated by protein kinase signaling pathways such as PKA and ERK MAPK. 24 
The cAMP/PKA pathway stimulates MITF promoter activity through the phosphorylation and activation 25 
of CREB, leading to an increase in MITF protein content. On the other hand, sustained ERK activation 26 
induces MITF phosphorylation and its subsequent degradation. Alisol B decreased the phosphorylation of 27 
CREB and continued to activate the MEK/ERK pathway, resulting in the reduction of MITF and 28 
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subsequent reduction of tyrosinase. In addition, alisol B had no effect on the activation of raf-1, which is 1 
an upstream positive modulator of the MEK/ERK pathway (data not shown), suggesting that raf-1 is not a 2 
target for alisol B. These results show that alisol B probably diminishes melanogenesis via two signaling 3 
pathways: the PKA-CREB-MITF pathway and the MEK-ERK-MITF pathway. 4 
In conclusion, we revealed that alisol B decreases MITF level through the regulation of the CREB and 5 
ERK pathways in B16 melanoma cells, leading to the inhibition of tyrosinase expression, and 6 
subsequently melanin production. These findings strongly suggest that alisol B can become a useful 7 
therapeutic agent for the treatment of hyperpigmentation, and can be used as an ingredient in whitening 8 
and lightening cosmetics. However, further research is required to evaluate the efficacy and safety of 9 
alisol B. 10 
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Figure legends 1 
Fig. 1. Identification of alisol B as an anti-melanogenic inhibitor. 2 
Notes: (A, B) After pretreatment with 8 compounds (10 μM) (Ctrl; 0.1% DMSO, 1; alisol B, 2; 3 
berberine chloride, 3; bergenin, 4; coptisine chloride, 5; corydaline, 6; glabridin, 7; loganin, 8; nodakenin), 4 
B16 melanoma cells were stimulated with a combination of forskolin (20 μM) and IBMX (100 μM) for 5 
72 hours. (A) The intracellular melanin content in B16 cells was measured as described under “Materials 6 
and methods”. (B) The cell viability was quantified by the MTT assay. Results are expressed relative to 7 
forskolin/IBMX-treated cells (closed bar) (=100%). Values are the means ± S.E. for at least four cultures, 8 
and statistical analysis was performed by one-way ANOVA with Tukey’s multiple comparison test. 9 
*p<0.05, **p<0.01, and ***p<0.001 compared with forskolin/IBMX stimulation. (C) Chemical structure 10 
of alisol B. 11 
 12 
Fig. 2. Effect of alisol B and A. rhizoma on melanogenesis in B16 cells. 13 
Notes: After pretreatment with DMSO (Ctrl), glabridin (1 μM), alisol B (1 μM), or A. rhizoma (10 14 
μg/ml), B16 cells were stimulated with forskolin (20 μM) and IBMX (100 μM) (A, C) or with α-MSH 15 
(0.1 μM) (B, D) for 72 hours, following which melanin content (A, B) and tyrosinase activity (C, D) were 16 
measured as described under “Materials and methods”. The results are expressed as means ± S.E. of three 17 
separate experiments, and statistical analysis was performed by one-way ANOVA with Tukey’s multiple 18 
comparison test. **p<0.01 and ***p<0.001 compared with forskolin/IBMX or α-MSH stimulation. 19 
 20 
Fig. 3. Inhibition of forskolin/IBMX-induced expression of tyrosinase and MITF by alisol B. 21 
Notes: (A, B) B16 cells were preincubated with alisol B (1 μM), and treated with forskolin/IBMX for 22 
72 hours. The mRNA expression level of tyrosinase (A) and MITF (B) was measured by real-time PCR 23 
analysis and was normalized to that of GAPDH. (C) B16 cells pretreated with alisol B were stimulated by 24 
forskolin/IBMX for 30 min and 60 min. The cell lysates were analyzed by immunoblotting using 25 
anti-MITF and anti-β-actin antibodies. The results are expressed as means ± S.E. of three separate 26 
experiments, and statistical analysis was performed by one-way ANOVA with Tukey’s multiple 27 
comparison test. ***p<0.001 compared with forskolin/IBMX stimulation. 28 
15 
 
 1 
Fig. 4. Alisol B suppressed forskolin/IBMX-induced melanin production through the regulation of CREB 2 
and MEK/ERK.  3 
Notes: B16 cells pretreated with alisol B were stimulated by forskolin/IBMX for 30 min and 60 min. 4 
The cell lysates were analyzed by immunoblotting using antibodies against CREB and phospho-CREB 5 
(A), ERK1/2 and phospho-ERK1/2 (B), and MEK1/2 and phospho-MEK1/2 (C). The levels of 6 
phosphorylated forms were normalized to the levels of total proteins. (D) B16 cells were pretreated with 1 7 
μM alisol B in the presence or absence of 10 μM U0126 for 30 min, followed by stimulation with 8 
forskolin/IBMX for 30 min. The cell lysates were analyzed by immunoblotting using anti-MITF and 9 
anti-β-actin antibodies. The results are expressed as means ± S.E. of three separate experiments. *p<0.05 10 
and **p<0.01 compared with forskolin/IBMX stimulation. 11 
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